Comparison of the Pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- And US-Approved versions of lantus insulin glargine in healthy subjects: Three randomized euglycemic clamp studies

Diabetes Care

Volumn 38, Issue 12, 2015, Pages 2226-2233

  Linnebjerg, Helle ^a   Lam, Eric Chen Quin ^b   Seger, Mary E ^a   Coutant, David ^a   Chua, Laiyi ^b   Chong, Chew Lan ^b   Ferreira, Maria M ^c   Soon, Danny ^b   Zhang, Xin ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c PAREXEL INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; LY2963016 INSULIN GLARGINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; EUROPE; FEMALE; GLUCOSE INFUSION; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; ANALOGS AND DERIVATIVES; ANALYSIS; CLINICAL TRIAL; COMPARATIVE STUDY; EUROPEAN UNION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; MIDDLE AGED; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EUROPEAN UNION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 84962360228     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2623     Document Type: Article

References (23)

1. Lantus [Internet], 2014. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000284/WC500036082.pdf. Accessed 21 July 2014.
2. U.S. Food and Drug Administration. Guidance for industry: clinical pharmacology data to support a demonstration of bio similarity to a reference product [Draft Guidance] [Internet], 2014. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf. Accessed 30 January 2015.
3. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues [Internet], 2014. Available from http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/04/WC500165988.pdf Accessed 30 January 2015.
4. U.S. Food and Drug Administration. Applications covered by Section 505(b)(2) [Draft Guidance] [Internet], 1999. Available from http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079345.pdf Accessed 7 August 2015.
5. European Medicines Agency. Assessment report: Abasria [Internet], 2014. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002835/WC500175383.pdfAccessed 29 January 2015.
6. Blevins T, Dahl D, Rosenstock J, et al. Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study (Abstract). Diabetes 2014;63(Suppl. 1):A19.
7. Rosenstock J, Hollander P, Bhargava A, et al. Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T2DM: The ELEMENT 2 Study (Abstract). Diabetes 2014;63(Suppl. 1):A17.
8. Morris AD, Ueda S, Petrie JR, Connell JM, Elliott HL, Donnelly R. The euglycaemic hyperinsulinaemic clamp: An evaluation of current methodology. Clin Exp Pharmacol Physiol 1997;24:513-518.
9. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008;294:E15-E26.
10. Owens DR. Human Insulin: Clinical Pharmacological Studies in Normal Man. New York, Springer Publishing, 1986.
11. Lucidi P, Porcellati F, Rossetti P, et al. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. Diabetes Care 2012;35: 2647-2649.
12. Eli Lilly and Company. European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe [Internet], 2014. Available from https://investor.lilly.com/releasedetail.cfm?ReleaseID=870088.Accessed 11 September 2014.
13. Shoda L, Kreuwel H, Gadkar K, et al. The Type 1 Diabetes Physio Lab Platform: A validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clin Exp Immunol 2010;161:250-267.
14. Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015;17:254-260.
15. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: Assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005;48:1988-1995.
16. Lucidi P, Porcellati F, Candeloro P, et al. Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose-response study. Nutr Metab Cardiovasc Dis 2014;24:709-716.
17. Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care 2012;35:2626-2630.
18. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53:1614-1620.
19. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49: 2142-2148.
20. Heise T, Zhang X, Lam ECQ, et al. Duration of action of 2 insulin glargine products, LY2963016 and Lantus, in subjects with type I diabetes mellitus (Abstract). Diabetes 2014;63(Suppl. 1):A228.
21. U.S. Food and Drug Administration. Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs: general considerations [Internet], 2014. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM389370.pdf. Accessed 7 May 2015.
22. European Medicines Agency. Guideline on the investigation of bioequivalence [Internet], 2010. Available from http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf Accessed 7 May 2015.
23. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutic review: Lantus [Internet], 2000. Available from http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/21081-Lantus-biopharmr.pdf. Accessed 21 October 2014.